{"disease":{"id":"obstructive-hypertrophic-cardiomyopathy-hcm","name":"obstructive hypertrophic cardiomyopathy hcm"},"drugs":{"marketed":[{"drug_id":"mavacamten","indication_name":"Obstructive hypertrophic cardiomyopathy (HCM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camzyos","generic_name":"MAVACAMTEN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"cardiac myosin","drug_class":"Cardiac Myosin Inhibitor [EPC]","quality_score":65,"revenue":"600","mechanism":"Mavacamten selectively inhibits cardiac myosin, reducing force-producing cross-bridge formation and improving cardiac function in HCM."},{"drug_id":"myk-461","indication_name":"Obstructive hypertrophic cardiomyopathy (HCM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Camzyos","generic_name":"MYK-461","company_name":"Myokardia Inc","drug_phase":"marketed","molecular_target":"Myosin-7","drug_class":"Cardiac Myosin Inhibitor [EPC]","quality_score":51,"revenue":null,"mechanism":"Camzyos works by inhibiting the Myosin-7 protein, which is involved in the thickening of heart muscle cells."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06609382","title":"Left Ventricular Mass Index Predicts Clinical Outcomes in Patients with Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy","phase":"","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"Changrong Nie","has_results":false},{"nct_id":"NCT05186818","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":282,"lead_sponsor_name":"Cytokinetics","has_results":true},{"nct_id":"NCT07529938","title":"Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":222,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT07383025","title":"Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05767346","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Cytokinetics","has_results":false},{"nct_id":"NCT07168655","title":"Mavacamten in Obstructive Hypertrophic Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":163,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07107373","title":"A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06338202","title":"Real-World Effectiveness of Mavacamten in Canada","phase":"","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07367724","title":"Ademetionine in Obstructive Hypertrophic Cardiomyopathy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}